|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Alzheimer's Disease | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Alzheimer Disease | |||||
| 3 | More general conditions related to this trial | ||||
| Brain Diseases | |||||
| Central Nervous System Diseases | |||||
| Delirium, Dementia, Amnestic, Cognitive Disorders | |||||
| Dementia | |||||
| Mental Disorders | |||||
| Nervous System Diseases | |||||
| Neurodegenerative Diseases | |||||
| Tauopathies | |||||
| 4 | Interventions listed in this trial | ||||
| raloxifene | |||||
| Placebo | |||||
| 5 | More general drug interventions related to this trial | ||||
| Bone Density Conservation Agents | |||||
| Estrogen Antagonists | |||||
| Estrogen Receptor Modulators | |||||
| Hormone Antagonists | |||||
| Hormones, Hormone Substitutes, and Hormone Antagonists | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Selective Estrogen Receptor Modulators | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute on Aging (NIA) | |||||
| Indiana University | |||||
| Kaiser Permanente | |||||
| Stanford University | |||||
| Southern Illinois University | |||||